Latest analysis of Imperative Care’s SYMPHONY-PE trial suggests early thrombectomy may improve key measures of heart recovery in intermediate-risk PE.

CAMPBELL, Calif., September 02, 2025--(BUSINESS WIRE)--Imperative Care, Inc. today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Symphony® Thrombectomy System to treat ...

Imperative Care has reported results from a post-hoc analysis of the SYMPHONY-PE trial, assessing the role of early ...

CAMPBELL, Calif.--(BUSINESS WIRE)--Imperative Care, Inc. today announced positive efficacy and safety results from the pivotal SYMPHONY-PE Trial (NCT06062329) evaluating the company’s Symphony® ...

A late-breaking study presented at the PERT Consortium 2025 Pulmonary Embolism Scientific Symposium in San Diego showed marked clot-burden reduction with no device-related serious adverse events for ...

Imperative Care, Inc., a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced the enrollment of the first patient in the CLEAR ...

Imperative Care also announced that more than 500 pulmonary embolism (PE) patients in the U.S. have been treated with the Symphony Thrombectomy System, reflecting growing physician adoption and ...